PDCD1 and skin squamous cell carcinoma: In line with contemporary international guidelines, PD-1 blockade with cemiplimab, and, where available, pembrolizumab, is endorsed as the preferred first-line systemic option for most patients with unresectable or metastatic cSCC, given its favorable efficacy–toxicity profile and the potential for durable disease control [7,10,19,99].